NCT05491057View on ClinicalTrials.gov

Treatment Patterns of Neratinib in HER2+ EBC in China

Not yet recruitingOBSERVATIONAL
Enrollment

500

Participants

Timeline

Start Date

September 30, 2022

Primary Completion Date

December 30, 2025

Study Completion Date

June 30, 2026

Conditions
Breast Cancer
Interventions
DRUG

Neratinib

Neratinib standard dose 240 mg once daily for 1 year

Trial Locations (1)

Unknown

Medical Affair, Shanghai

All Listed Sponsors
lead

Pierre Fabre Medicament

INDUSTRY

NCT05491057 - Treatment Patterns of Neratinib in HER2+ EBC in China | Biotech Hunter | Biotech Hunter